Trial Profile
A clinical study of LBT-3627
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs LBT-3627 (Primary)
- Indications Neurodegenerative disorders; Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics
- 27 Jul 2018 New trial record
- 16 Jul 2018 According to a Longevity Biotech media release, this trial will be launched at the Corporal Michael J. Crescenz Veterans Affairs Medical Center (CMCVAMC) Parkinson's Disease Research Education and Clinical Center (PADRECC) and supported by The Michael J. Fox Foundation for Parkinson's Research.